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A naplastic large cell lymphoma (ALCL) is a T-cell or null-phenotype lymphoma.  Most cases 
have t(2;5)(p23;q25),  which results in a fusion 
between the anaplastic lymphoma kinase (ALK) gene 
at chromosome band 2 and the nucleophosmin (NPM) 
gene at chromosome band 5.  This fusion increases the 
activity of the ALK protein,  which results in the pro-
liferation of ALCL cells.
　 Childhood ALCL accounts for 10–20  of childhood 
non-Hodgkin lymphoma cases,  and the advanced stages 
(stage III and IV) of childhood ALCL were reported 
to have a 2-year event-free survival (EFS) rate of 
70–80 .  Standard therapy for patients with stage I 
or II ALCL who have undergone a total resection of 
the tumor is only three courses of intensive combined 
chemotherapy,  whereas patients at other advanced 
stages of cancer often receive 6 courses of chemo-
therapy.  Hematopoietic stem cell transplantation 
(HSCT) is not recommended as a ﬁrst-line therapy for 
ALCL [1–3].  The BFM,  SIOP,  and UKCCSG ret-
rospective studies demonstrated that invasion to the 
mediastinum,  skin,  liver,  and lung were risk factors 
for a poor prognosis of ALCL [4].
　 Here,  we report 2 patients who relapsed 6 to 18 
months after the end of ALCL99 therapy [5].  Our 
analysis of stored samples taken at the initial diagnosis 
identiﬁed the NPM-ALK fusion gene in both patients.  
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Childhood anaplastic large cell lymphoma (ALCL) accounts for approx.  10–30  of cases of non-Hod-
gkin lymphoma,  and the ALCL99 study reported 60–75  disease-free survival; however,  a relatively 
high relapse rate was observed (25–30 ).  We report 2 patients with Stage III ALCL who relapsed 6–18 
months after the end of ALCL99 chemotherapy.  A retrospective molecular analysis identiﬁed the nuc-
leophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the ﬁrst diagnostic bone marrow 
samples taken from both patients.  However,  antibodies against the ALK protein appeared to be rela-
tively low in the serum of both patients (×100 and ×750).  An increase in chemotherapy intensity may 
be beneﬁcial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the ﬁrst diag-
nostic bone marrow sample.
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The prognostic impact of monitoring the NPM-ALK 
chimera will also be discussed.
Case Report
　 Patient 1. In September 2010,  a 15-year-old 
Japanese female presented with fever and swelling of 
the cervical lymph nodes,  cervix,  axillae,  supracla-
vicular ﬁssure,  mediastinum,  hilus,  paravertebrae,  
and the upper abdomen (Fig. 1A).  Because she was in 
critical condition on admission,  positron emission 
tomography (PET) images could not be obtained.  The 
diagnosis of Stage III ALCL was made by lymph node 
biopsy.  Horseshoe-shaped large cells were positive for 
both CD30 and ALK in the nucleus and cytoplasm 
(Fig. 2A,B).  Bone marrow (BM) aspirate was normal,  
and no malignancy was observed in the cerebrospinal 
ﬂuid.  She had achieved complete remission after 
undergoing the ALCL99 regimen; but 8 months after 
the end of chemotherapy,  relapse was conﬁrmed in the 
right inguinal lymph node.  She was treated by with the 
Berlin-Frankfurt-Munster (BFM) regimen and 
achieved a second complete remission [1].
　 The patient eventually underwent an unrelated bone 
marrow transplantation (BMT) with a conditioning 
regimen of etoposide (VP16),  endoxan (CY),  and total 
body irradiation (TBI).  Graft-versus-host disease 
(GVHD) prophylaxis of tacrolimus and short-term 
methotrexate was administered.  She transiently suf-
fered from pure red cell aplasia from an unknown 
cause,  but she has maintained complete remission for 
38 months since the BMT.
　 Patient 2. A 14-year and 5-month-old Japanese 
female presented with fever and lymph node swelling 
throughout her entire body in May of 2011 (Fig. 1B).  
Computed tomography (CT) and PET CT showed 
enlarged lymph nodes both above and below the dia-
phragm,  and invasion into the left adrenal grand.  The 
diagnosis of ALCL was made based on the lymph node 
biopsy.  Large cells positive for CD30 and ALK in 
both the nucleus and cytoplasm were observed (Fig. 
2C,D).  BM aspirate demonstrated normocellular mar-
row,  and no malignant evidence found in the cerebro-
spinal ﬂuid.
　 She achieved a ﬁrst complete remission by ALCL99;  
however,  relapse occurred in multiple lymph nodes,  
observed by CT 18 months after the end of the chemo-
therapy.  She underwent a BMT with a conditioning 
regimen of VP16,  CY,  and TBI.  GVHD prophylaxis 
of cyclosporine A and short-term methotrexate was 
administered.  She has maintained complete remission 
for 33 months since the BMT.
　 The Histopathological Examinations.
Biopsy samples were stained with hematoxylin and 
eosin.  The immunohistochemical analysis was per-
formed using an automatic immunostainer (Ventana 
Medical Systems,  Tucson,  AZ,  USA) with CD30 
(Ber-H2) (Dako,  Carpenteria,  CA,  USA),  ALK,  
CD2,  CD3 (polyclonal),  CD5,  CD43,  CD15,  CD20,  
CD79a,  CD45RO(UCHL-1),  CD45(LCA),  S-100,  
TIA-1,  Granzyme B,  Ki-67 and epithelial membrane 
antigen (EMA; Dako) antibodies.
　 Quantification of NPM-ALK Chimera by 
Real-time PCR and ALK antibody. We inves-
tigated the presence of the NPM-ALK chimera by 
conducting a real-time polymerase chain reaction 
(PCR),  and we measured the antibody response to 
ALK as described [6,7].  The copy number of the 
NPM-ALK fusion transcript was normalized by 104 
copies of ABL,  and the antibody dilutions used were 
1/50,  1/100,  1/250,  1/750,  1/6,750,  1/20,250,  
and 1/60,750.  Informed consent was obtained from the 
504 Kanazawa et al. Acta Med.  Okayama　Vol.  70,  No.  6
Fig.  1　 A,  Swelling of the lymph nodes in the postcervical 
space,  supraclavicular ﬁssure,  axillae,  lesser curvature of stomach,  
mesenteries,  and around the para-aortic area of the internal and 
external iliac artery in Patient 1.  No malignancy was observed in 
extranodal sites of the brain,  lung,  liver,  spleen,  or bone; B,  
Lymph nodes were enlarged above and below the diaphragm.  
Invasion was observed in the left adrenal grand in Patient 2.  No 
malignancy was observed in the liver,  spleen,  or bone.
patientsʼ parents,  and approval was obtained for this 
study from the Ethics Committee of our institution.
　 In Patient 1,  the copy number of NPM-ALK was 90 
copies/10,000 copies of ABL in the BM,  and 1,278 
copies/10,000 copies of ABL in the peripheral blood 
(PB) at the initial diagnosis.  On the other hand,  the 
antibody titer of ALK was ×100 times at diagnosis.  
NPM-ALK in the BM was shown to be positive by 
reverse transcribed (RT)-PCR (the titer was too low 
to measure by real-time PCR) at relapse,  and NPM-
ALK in the BM was negative before BMT.
　 In Patient 2,  the copy number of NPM-ALK was 92 
copies/10,000 copies of ABL in the BM; however,  
NPM-ALK was not detected in the PB at initial diag-
nosis.  The antibody titer of ALK was ×750 times at 
diagnosis,  and ×2,250 times at relapse.  Due to the 
lack of a sample,  NPM-ALK could not be examined in 
the relapsed BM of Patient 2.
Discussion
　 We report 2 cases of relapsed stage III ALCL.  
Although both patients achieved complete remission by 
the ALCL99 regimen,  they relapsed after the end of 
chemotherapy.  Both patients were successfully 
treated with HSCT,  and they survived without dis-
ease.  As described above,  we consider allogeneic 
HSCT for relapsed ALCL patients based on the 
results of a retrospective study of Japanese childhood 
ALCL [8].  The possibility of performing autologous 
HSCT remained when the minimal residual disease 
(MRD) was negative,  but it was reported that a rela-
tively high relapse rate was observed in ALCL 
patients with autologous HSCT compared to those of 
allogeneic HSCT,  and we therefore chose allogeneic 
HSCT in the present 2 cases.
　 The NPM-ALK chimera was identiﬁed in BM sam-
ples from the initial diagnosis in both of our patients,  
although BM invasion was negative by usual examina-
tion.  In addition,  ALK antibodies were relatively low 
in samples from the initial diagnosis in both patients.
　Mussolin et al. reported that in ALCL patients with 
NPM-ALK chimera and minimal disseminated disease 
(MDD) shown by RT-PCR,  the 5-year progres-
sion-free survival was 41±11  for patients with 
positive BM versus 100  for patients with negative 
BM [9].  Damm Welk et al.  reported that ALCL 
patients whose BM was NPM-ALK-positive by RT-PCR 
showed a higher cumulative incidence of relapse than 
those who were NPM-ALK negative [6,10].  Mussolin 
et al.  proposed that a low ALK antibody titer was 
correlated with relapse,  and patients were classiﬁed 
in a high-risk group when they were MDD-positive and 
had an antibody titer 1/750 [11].  The autologous 
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Fig.  2　 In Patient 1,  the nucleus of the large,  atypical cells had a “horseshoe” , “fetal” shape (A).  In the immunohistochemical study,  
the cells were CD20(－),  CD3(－),  CD30(＋),  S100(－),  and ALK-positive in both the nucleus and cytoplasm (B).  In Patient 2,  growing 
cells showed an enlarged cytoplasm,  creating a clear boundary between the large nucleus and cytoplasm,  and were observed around 
(interfollicular and sinus) normal lymph follicles (C).  In the immunohistochemical study,  the cells were CD20(－),  CD3(－),  CD30(＋),  and 
ALK-positive in both the nucleus and cytoplasm.  (D) Cells were TIA-1(＋),  Granz B(＋),  and highly Ki-67 (＋).
anti-ALK antibodies were produced by NPM-ALK 
oncogenic fusion protein,  and the strength of the ALK 
autoantibody response was inversely correlated with 
stage and tumor dissemination,  as well as with the risk 
of relapse [7].
　 MDD in childhood ALCL detected by qualitative 
RT-PCR was reported to be a strong risk factor for a 
poor prognosis,  and it was also observed to be cor-
related with minimal residual disease (MRD) and the 
ALK antibody titer [12-14].  In our Patient 1,  NPM-
ALK was negative in the MRD,  prior to BMT.
　 Although it remains to be clariﬁed what percentage 
of patients with Stage III ALCL have MDD-positive 
BM by real-time PCR,  the EFS rate in advanced 
ALCL patients was reported to be approx.  25 [15].  
Although we did not monitor MDD in the present two 
cases,  the survival rate for MDD-positive patients 
might improve in the future with the use of combined 
treatment,  such as TKI targeting ALK and/or HSCT.
　 In conclusion,  we report the cases of 2 patients 
with relapsed stage III ALCL who were successfully 
treated by HSCT.  Both showed the presence of the 
NPM-ALK chimera and low ALK antibody at diagno-
sis.
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